Eylea (aflibercept) 8 mg is now listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) in adults, based on positive results from the pivotal PULSAR and PHOTON studies.1-3
Eylea 8 mg treatment is initiated with one injection per month for three consecutive months, followed by one injection every eight to 16 weeks based on the ophthalmologist’s judgment of visual and/or anatomical outcomes.1 Treatment with intervals of one month for more than three consecutive months has not been studied.1 Safety of Eylea 8 mg was similar to Eylea 2 mg in both studies, with no new safety signals identified.1-3
Contact: Bayer Account Manager
Please review the Eylea Product Information before prescribing, available by scanning the QR code or contacting Bayer Medical Information on (AUS) 1800 008 757.
PBS Information |
|---|
| Eylea 8 mg: Authority required for the treatment of wet age-related macular degeneration and
diabetic macular oedema. Eylea 2 mg: Authority required for the treatment of wet age-related macular degeneration, diabetic macular oedema, central retinal vein occlusion, and branch retinal vein occlusion, myopic choroidal neovascularisation. Refer to PBS schedule for full Authority Required information.
|
References
- Eylea Approved Product Information. 2. Lanzetta P, et al. Lancet 2024. doi: 10.1016/S0140-6736(24)00063-1.
- Brown DM et al. Lancet 2024. doi: 10.1016/S0140-6736(23)02577-1.
March 2025. PP-EYL_8mg-AU-0184-1.
